Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LISAH: SC Trastuzumab Injection Sites in Early Breast Cancer
NCT01928615Phase 2Terminated
- Sponsor
- Roche
- Start
- Sep 2013
- Primary completion
- Oct 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Quality of Life Score. Started Sep 2013; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01928615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01928615.